Authentix Partners with AstraZeneca to Protect Drug Supply with Unit-Level Mass Serialisation

DALLAS & YORK, U.K.--(BUSINESS WIRE)--Mar 7, 2007 - Authentix, Inc.(R), announced that it is working with longtime partner, AstraZeneca, to safeguard patients and to protect the integrity of the legitimate supply chain with the rollout of unit-level serialised tamper evident security seals (TESS) combined with unique carton numbers (UCN). When the Serialised Authentication Program launches next quarter, AstraZeneca will become one of the first pharmaceutical companies to implement a comprehensive system to serialise and authenticate its pharmaceutical products down to the unit-level.

The Serialised Authentication Programme for NEXIUM assigns unique serialised codes to each tablet blister pack via the carton and the associated tamper evident seal. Once a serialised code is assigned, it is activated, validated, and entered into a database where it can be cross-checked against all serialised codes throughout the AstraZeneca supply chain.

In November 2006, the European Federation of Pharmaceutical Industries and Associations (EFPIA) endorsed serialisation as the most promising solution to fight counterfeiting and illegal diversion threats in Europe and globally. The EFPIA maintains that serialisation offers greater security, enhances tracking, and will work easily with Radio Frequency Identification (RFID) technologies when RFID matures.

"The Serialised Authentication Programme gives AstraZeneca the potential to monitor our supply chain. Furthermore, working with other pharma companies, industry bodies and government agencies, the system will eventually help facilitate the identification or verification of products across the entire supply chain, from the point of manufacture to the point of dispensing," says David Teale, Director of Product Security, AstraZeneca. "In addition, the programme can be combined with other brand protection requirements for field authentication and tamper evidence."

"By becoming one of the first pharmaceutical companies to employ large-scale mass serialisation, AstraZeneca is leading the way" says Jim Rittenburg, Vice President of Healthcare and Life Sciences, Authentix. "AstraZeneca is showing patients that they are committed to being at the forefront of the fight against pharmaceutical counterfeiting."

The Serialised Authentication Programme is the result of several years of collaborative work between Authentix and AstraZeneca which has resulted in a number of diverse regional authentication and serialisation solutions that help safeguard AstraZeneca products, and ultimately, the patients who depend on them.

ABOUT AUTHENTIX

Authentix(R) is the Global Leader in authentication solutions for brand protection and fiscal recovery. As the inventor and developer of many of the leading nano-scale authentication solutions in use today, we have a world-class technology portfolio. Moreover, our skills in applying those technologies to solve counterfeit, adulteration and smuggling issues for clients, ensures that we are a trusted partner of many of the world's leading brand owners and governments. In the last four years we have recovered over $4 billion in lost revenues in the oil and gas, pharmaceutical and consumer goods industries alone. In addition, our expertise in the fields of value documents, currency and homeland security applications aids in the protection and betterment of society.

Contact

Authentix
Cari Weinberg, 469-737-4453
Manager, Public Relations
cari.weinberg@authentix.com

Posted: March 2007


View comments

Hide
(web4)